3B Blackbio

What does 3B Blackbio do?

3B Blackbio DX Ltd is a small-cap healthcare services company specializing in the manufacturing of pesticide products, microfertilizers, biofertilizers, and biopesticides. As of March 2025, it reported net sales of 22 Cr and a net profit of 8 Cr, with a market cap of Rs 1,390 Cr.

Overview: <BR>3B Blackbio DX Ltd operates in the healthcare services industry as a small-cap company, focusing on the manufacturing of pesticide products, microfertilizers, biofertilizers, and biopesticides.<BR><BR>History: <BR>Incorporated on May 25, 1972, the company was formerly known as Kilpest India Ltd. It has evolved from being a leading agri-based company in Madhya Pradesh to a significant player in Central India. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 22 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 8 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 1,390 Cr (Small Cap) <BR><BR>Key Metrics: <BR>P/E: 30.00 <BR>Industry P/E: 38 <BR>Dividend Yield: 0.18% <BR>Debt-Equity: -0.26 <BR>Return on Equity: 17.73% <BR>Price to Book: 5.31 <BR><BR>Contact Details: <BR>Address: 7-C Industrial Area, Govindpura Bhopal Madhya Pradesh : 462023 <BR>Tel: 91-0755-2586536/2586537 <BR>Email: kilpestbpl@yahoo.co.in/kilpest@bsnl <BR>Website: http://www.kilpest.com

Who are in the management team of 3B Blackbio?

As of March 2022, the management team of 3B Blackbio includes D K Dubey (Chairman & Managing Director), N K Dubey (Whole-time Director), Shabbar Husain, Abdul Moin Khan, and Harihar Prasad Thapak (Independent Directors), Mithala Dubey (Non-Executive Director), and Navneet Kaur (Company Secretary & Compliance Officer).

As of March 2022, the management team of 3B Blackbio includes the following members:<BR><BR>1. D K Dubey - Chairman & Managing Director<BR>2. N K Dubey - Whole-time Director<BR>3. Shabbar Husain - Independent Director<BR>4. Mithala Dubey - Non Executive Director<BR>5. Navneet Kaur - Company Secretary & Compliance Officer<BR>6. Abdul Moin Khan - Independent Director<BR>7. Harihar Prasad Thapak - Independent Director<BR><BR>These individuals play key roles in the governance and management of the company.

Has 3B Blackbio declared dividend?

Yes, 3B Blackbio DX Ltd has declared a 30% dividend, amounting to 3 per share, with an ex-date of September 17, 2024. Recent total returns show volatility, with a -16.3% return over the last 6 months but strong performance over longer periods, including a 1282.3% return over the past 5 years.

3B Blackbio DX Ltd has declared a 30% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 30%<BR>- Amount per share: 3 per share<BR>- Ex-date: 17 Sep 24<BR><BR>Dividend Yield: 0.18%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -16.3%, with a dividend return of 0%, resulting in a total return of -16.3%.<BR><BR>Over the past year, the price return was 78.18%, the dividend return was 0.26%, leading to a total return of 78.44%.<BR><BR>In the 2-year period, the price return was 286.4%, the dividend return was 1.30%, culminating in a total return of 287.7%.<BR><BR>For the 3-year period, the price return was 368.71%, with a dividend return of 2.40%, resulting in a total return of 371.11%.<BR><BR>In the last 4 years, the price return was 278.08%, the dividend return was 2.66%, leading to a total return of 280.74%.<BR><BR>Finally, over the past 5 years, the price return was 1273.79%, with a dividend return of 8.51%, resulting in a total return of 1282.3%.<BR><BR>Overall, while 3B Blackbio DX Ltd has declared a dividend, the recent total returns indicate significant volatility, particularly in the short term, contrasting with strong performance over longer periods.

Who are the peers of the 3B Blackbio?

3B Blackbio's peers include Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Sastasundar Ven., Prevest Denpro, Nureca, and Bilcare. 3B Blackbio leads in 1-year return at 84.89%, while Bilcare has the lowest at 37.08%, and all peers except Bilcare have excellent capital structures.

Peers: The peers of 3B Blackbio are Syngene Intl., Dr Lal Pathlabs, Poly Medicure, Indegene, Vijaya Diagnost., Sastasundar Ven., Prevest Denpro, Nureca, and Bilcare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Dr Lal Pathlabs, while Good management risk is found at Syngene Intl., Poly Medicure, Indegene, and Vijaya Diagnost., and Average management risk is seen at 3B Blackbio, Prevest Denpro, and Nureca. Below Average management risk is noted for Sastasundar Ven. and Bilcare. Growth is Excellent at 3B Blackbio, while Average growth is found at Poly Medicure, Indegene, and Sastasundar Ven., and Below Average growth is observed at Syngene Intl., Dr Lal Pathlabs, Vijaya Diagnost., Prevest Denpro, Nureca, and Bilcare. All peers have Excellent capital structure except for Bilcare, which has Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is 3B Blackbio at 84.89%, while the peer with the lowest is Bilcare at 37.08%. Compared to its peers, 3B Blackbio has a significantly higher 1-year return. Additionally, the six-month return is negative for Syngene Intl., Poly Medicure, Vijaya Diagnost., Sastasundar Ven., Prevest Denpro, and Nureca.

Is 3B Blackbio overvalued or undervalued?

As of August 11, 2022, 3B Blackbio is considered very expensive and overvalued, with a PE ratio of 29.13, an EV to EBITDA of 26.29, and a PEG ratio of 1.04, despite having a lower PE ratio than Bayer CropScience and P I Industries, but higher than UPL, while its stock has declined 19.90% year-to-date compared to the Sensex's 5.63% gain.

As of 11 August 2022, the valuation grade for 3B Blackbio has moved from fair to very expensive, indicating a significant shift in its market perception. The company is currently deemed overvalued. Key ratios include a PE ratio of 29.13, an EV to EBITDA of 26.29, and a PEG ratio of 1.04, which suggest that the stock is trading at a premium compared to its earnings growth potential.<BR><BR>In comparison to its peers, 3B Blackbio's PE ratio is lower than that of Bayer CropScience at 43.48 and P I Industries at 35.59, both of which are also classified as very expensive. However, it is notably higher than UPL, which is rated as attractive with a PE ratio of 38.74. Recent stock performance shows a decline of 19.90% year-to-date, contrasting sharply with the Sensex's gain of 5.63%, reinforcing the notion that the stock may be overvalued in the current market context.

Who are the top shareholders of the 3B Blackbio?

The top shareholders of 3B Blackbio include Mithla Dubey with 12.35%, Rashi Daga with 5.3%, and individual investors holding 43.17%. There are no pledged promoter holdings or mutual funds involved.

The top shareholders of 3B Blackbio include Mithla Dubey, who holds the highest stake among promoters at 12.35%. The highest public shareholder is Rashi Daga, with a holding of 5.3%. Additionally, individual investors collectively own 43.17% of the company. There are also three foreign institutional investors (FIIs) that hold a combined 2.7%. Notably, there are no pledged promoter holdings and no mutual funds involved in the shareholding.

How big is 3B Blackbio?

As of 24th July, 3B Blackbio DX Ltd has a market capitalization of 1,282.00 Cr, with recent net sales of 96.47 Cr and a net profit of 47.58 Cr. Shareholder's funds are valued at 223.05 Cr, and total assets amount to 248.10 Cr.

As of 24th July, 3B Blackbio DX Ltd has a market capitalization of 1,282.00 Cr, classifying it as a Small Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 96.47 Cr and a Net Profit of 47.58 Cr.<BR><BR>For the latest annual period ending March 2024, the Shareholder's Funds were valued at 223.05 Cr, while Total Assets amounted to 248.10 Cr.

Are 3B Blackbio latest results good or bad?

3B Blackbio's latest results show mixed performance: improved operational efficiency and higher liquidity are positive, but slowing growth in net sales and profits raises concerns. MarketsMOJO has issued a 'Sell' call, indicating a cautious outlook on the company's future.

3B Blackbio DX's latest financial results show a mixed performance. On the positive side, the company has improved its operational efficiency, as indicated by a higher Debtors Turnover Ratio of 2.64 times, which suggests that it is managing its receivables more effectively. Additionally, cash and cash equivalents have reached Rs 68.83 crore, the highest in the last three half-yearly periods, indicating stronger short-term liquidity.<BR><BR>However, there are some concerns as well. The year-over-year growth in net sales has decreased to 14.41% from 36.06% in the previous year, and the consolidated net profit growth has also slowed to 13.12% compared to 52.67% last year. This downward trend in growth rates could be a cause for caution.<BR><BR>Despite these positive operational improvements, MarketsMOJO has issued a 'Sell' call on the stock, reflecting a cautious outlook on the company's future performance. Overall, while there are some encouraging signs, the slowing growth rates and market sentiment suggest that the results might not be viewed as entirely positive.

When is the next results date for 3B Blackbio?

The next results date for 3B Blackbio is 13 November 2025.

The next results date for 3B Blackbio is scheduled for 13 November 2025.

How has been the historical performance of 3B Blackbio?

3B Blackbio has shown significant improvement in financial performance, with net sales rising from 61.84 Cr in Mar'23 to 96.47 Cr in Mar'25, and profit after tax increasing from 25.94 Cr to 47.69 Cr during the same period, alongside reduced expenditures and enhanced cash flow. Overall, the company has demonstrated recovery and growth in its financial metrics.

Answer:<BR>The historical performance of 3B Blackbio shows a fluctuating trend in net sales and profitability over the years, with recent improvements noted.<BR><BR>Breakdown:<BR>3B Blackbio's net sales have increased from 61.84 Cr in Mar'23 to 96.47 Cr in Mar'25, following a dip in Mar'22. The total operating income also reflects this upward trend, reaching 96.47 Cr in Mar'25. The company has managed to reduce its total expenditure, which was 76.75 Cr in Mar'21, down to 46.36 Cr in Mar'25. Consequently, the operating profit (PBDIT) has significantly improved, rising from 29.15 Cr in Mar'23 to 50.11 Cr in Mar'25. Profit before tax has also shown a positive trajectory, increasing from 35.31 Cr in Mar'23 to 64.00 Cr in Mar'25, while profit after tax has grown from 25.94 Cr in Mar'23 to 47.69 Cr in Mar'25. The company's total assets have expanded from 214.06 Cr in Mar'23 to 295.72 Cr in Mar'25, indicating a solid growth in financial standing. Cash flow from operating activities has also improved, reaching 43.00 Cr in Mar'25, contributing to a net cash inflow of 6.00 Cr for the same period. Overall, 3B Blackbio has demonstrated a recovery and growth in its financial metrics over the recent years.

Is 3B Blackbio technically bullish or bearish?

As of November 17, 2025, 3B Blackbio's trend has shifted to a bearish stance with moderate strength, supported by daily moving averages and Bollinger Bands, despite mixed signals from the MACD across different time frames.

As of 17 November 2025, the technical trend for 3B Blackbio has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this conclusion include the daily moving averages indicating bearish momentum, and the weekly and monthly Bollinger Bands also signaling bearish conditions. The MACD shows a mildly bullish signal on the weekly chart but is mildly bearish on the monthly, indicating mixed signals across time frames. Overall, the bearish trend is reinforced by the Dow Theory, which is mildly bearish on both weekly and monthly assessments.

Should I buy, sell or hold 3B Blackbio DX Ltd?

Why is 3B Blackbio DX Ltd falling/rising?

As of 02-Feb, the stock price of 3B Blackbio DX Ltd is currently at 1,525.00, reflecting a significant decline and underperformance compared to the sector. The stock has seen consecutive losses, a decrease in investor confidence, and poor long-term growth, leading to concerns about its future prospects.

As of 02-Feb, the stock price of 3B Blackbio DX Ltd is falling, currently at 1,525.00, which reflects a decrease of 90.3 points or 5.59%. This decline is part of a broader trend, as the stock has underperformed the sector by 7.89% today and has experienced consecutive losses over the last two days, totaling an 8.54% drop during this period. <BR><BR>The stock's performance over the past week shows a decline of 6.82%, while its one-year performance reveals a significant drop of 17.34%, contrasting sharply with the Sensex, which has gained 5.37% in the same timeframe. Additionally, the stock's trading activity indicates a lack of investor confidence, as delivery volume has decreased by 53.57% compared to the five-day average, suggesting reduced participation from investors.<BR><BR>Financially, the company has shown poor long-term growth, with net sales declining at an annual rate of 10.27% and operating profit decreasing by 16.77% over the last five years. Despite a return on equity of 16.5%, the stock is considered expensive with a price-to-book value of 4.4, which is higher than its peers. This premium valuation, combined with the company's underperformance in the market and the lack of investment from domestic mutual funds, indicates that investors may be wary of the stock's future prospects, contributing to its current decline.

Which are the latest news on 3B Blackbio?